Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 14/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | USP1 | O94782 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22105361 | 0.99 | P2RX3 (0.32) | PDE5AP2RX3ADORA3PDE4APDE4B | |
| SCHEMBL22105851 | 0.92 | ADORA3 (0.32) | ADORA3 | |
| SCHEMBL24092237 | 0.91 | P2RX3 (0.35) | PDE5AP2RX3ADORA3PDE4APDE4B | |
| SCHEMBL24495686 | 0.87 | PDE5A (0.37) | PDE5AP2RX3ADORA3PDE4APDE4B | |
| SCHEMBL22105531 | 0.87 | ADORA3 (0.33) | PDE5AADORA3PDE4APDE4BPDE4C | |
| SCHEMBL24092238 | 0.86 | P2RX3 (0.35) | P2RX3 | |
| SCHEMBL22105423 | 0.82 | P2RX3 (0.35) | PDE5AP2RX3 | |
| SCHEMBL22105716 | 0.81 | ADORA3 (0.33) | PDE5AADORA3PDE4APDE4BPDE4C | |
| SCHEMBL22105742 | 0.80 | P2RX3 (0.33) | PDE5AP2RX3 | |
| SCHEMBL22105553 | 0.78 | ADORA3 (0.40) | PDE5AADORA3PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198696-B2 | Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-14 | — | — | US | disclosed |
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | PDE5A 468/4885P2RX3 9/4885ADORA3 114/4885 |
| US-11198696-B2 | Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity | TRPC5, TRPM5, TRPC4 | PDE5A 354/4885P2RX3 24/4885ADORA3 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.